Does the media prefer ONC or SYRE?

In the previous week, BeOne Medicines had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for BeOne Medicines and 10 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.32 beat BeOne Medicines' score of -0.46 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MRNA or SYRE?

In the previous week, Moderna had 24 more articles in the media than Spyre Therapeutics. MarketBeat recorded 34 mentions for Moderna and 10 mentions for Spyre Therapeutics. Moderna's average media sentiment score of 0.37 beat Spyre Therapeutics' score of 0.32 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 13 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 9 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SYRE or ROIV?

In the previous week, Spyre Therapeutics had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Spyre Therapeutics and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.35 beat Spyre Therapeutics' score of 0.32 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SYRE or BNTX?

In the previous week, Spyre Therapeutics had 8 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for Spyre Therapeutics and 2 mentions for BioNTech. BioNTech's average media sentiment score of 0.85 beat Spyre Therapeutics' score of 0.32 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INSM or SYRE more profitable?

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Spyre Therapeutics' return on equity of -42.88% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Spyre Therapeutics N/A -42.88% -27.76%

Does the media favor INSM or SYRE?

In the previous week, Insmed had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Insmed and 10 mentions for Spyre Therapeutics. Insmed's average media sentiment score of 1.17 beat Spyre Therapeutics' score of 0.32 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Spyre Therapeutics (SYRE) Competitors

$86.24 -10.81 (-11.14%)

Closing price 04:00 PM Eastern

Extended Trading

$84.36 -1.88 (-2.18%)

As of 07:57 PM Eastern

Compare

SYRE vs. ONC, MRNA, ROIV, BNTX, and INSM

Should you buy Spyre Therapeutics stock or one of its competitors? MarketBeat compares Spyre Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spyre Therapeutics include BeOne Medicines (ONC), Moderna (MRNA), Roivant Sciences (ROIV), BioNTech (BNTX), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Spyre Therapeutics compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

BeOne Medicines presently has a consensus target price of $390.00, suggesting a potential upside of 40.73%. Spyre Therapeutics has a consensus target price of $95.83, suggesting a potential upside of 11.12%. Given BeOne Medicines' higher probable upside, equities analysts plainly believe BeOne Medicines is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

BeOne Medicines has a net margin of 8.94% compared to Spyre Therapeutics' net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Spyre Therapeutics	N/A	-42.88%	-27.76%

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BeOne Medicines had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for BeOne Medicines and 10 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.32 beat BeOne Medicines' score of -0.46 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	62.00
Spyre Therapeutics	$890K	8,414.70	-$155.20M	-$2.08	N/A

BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market.

Summary

BeOne Medicines beats Spyre Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Moderna currently has a consensus target price of $36.60, suggesting a potential downside of 39.42%. Spyre Therapeutics has a consensus target price of $95.83, suggesting a potential upside of 11.12%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spyre Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market.

In the previous week, Moderna had 24 more articles in the media than Spyre Therapeutics. MarketBeat recorded 34 mentions for Moderna and 10 mentions for Spyre Therapeutics. Moderna's average media sentiment score of 0.37 beat Spyre Therapeutics' score of 0.32 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	13 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	9 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyre Therapeutics has lower revenue, but higher earnings than Moderna. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	12.33	-$2.82B	-$8.15	N/A
Spyre Therapeutics	$890K	8,414.70	-$155.20M	-$2.08	N/A

75.3% of Moderna shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Spyre Therapeutics has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Summary

Spyre Therapeutics beats Moderna on 11 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to Roivant Sciences?

Spyre Therapeutics (NASDAQ:SYRE) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Spyre Therapeutics currently has a consensus target price of $95.83, indicating a potential upside of 11.12%. Roivant Sciences has a consensus target price of $33.59, indicating a potential downside of 1.23%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Spyre Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Spyre Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Spyre Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

In the previous week, Spyre Therapeutics had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Spyre Therapeutics and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.35 beat Spyre Therapeutics' score of 0.32 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has higher earnings, but lower revenue than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,414.70	-$155.20M	-$2.08	N/A
Roivant Sciences	$8.26M	2,961.55	-$299.77M	-$0.60	N/A

Summary

Spyre Therapeutics beats Roivant Sciences on 11 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to BioNTech?

Spyre Therapeutics (NASDAQ:SYRE) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Spyre Therapeutics has higher earnings, but lower revenue than BioNTech. Spyre Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,414.70	-$155.20M	-$2.08	N/A
BioNTech	$3.25B	7.03	-$1.29B	-$5.88	N/A

Spyre Therapeutics currently has a consensus target price of $95.83, indicating a potential upside of 11.12%. BioNTech has a consensus target price of $129.56, indicating a potential upside of 43.62%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Spyre Therapeutics has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
BioNTech	-44.39%	-5.30%	-4.62%

Spyre Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

In the previous week, Spyre Therapeutics had 8 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for Spyre Therapeutics and 2 mentions for BioNTech. BioNTech's average media sentiment score of 0.85 beat Spyre Therapeutics' score of 0.32 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spyre Therapeutics beats BioNTech on 9 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

80.4% of Spyre Therapeutics shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Spyre Therapeutics' return on equity of -42.88% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Insmed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market.

In the previous week, Insmed had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Insmed and 10 mentions for Spyre Therapeutics. Insmed's average media sentiment score of 1.17 beat Spyre Therapeutics' score of 0.32 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Insmed presently has a consensus target price of $211.86, indicating a potential upside of 104.81%. Spyre Therapeutics has a consensus target price of $95.83, indicating a potential upside of 11.12%. Given Insmed's higher probable upside, equities research analysts plainly believe Insmed is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Spyre Therapeutics has lower revenue, but higher earnings than Insmed. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.97	-$1.28B	-$5.75	N/A
Spyre Therapeutics	$890K	8,414.70	-$155.20M	-$2.08	N/A

Summary

Spyre Therapeutics beats Insmed on 11 of the 17 factors compared between the two stocks.

Get Spyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYRE vs. The Competition

Export

Metric	Spyre Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.43B	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-41.46	20.50	25.39	23.96
Price / Sales	8,414.70	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	11.96	8.26	10.76	6.41
Net Income	-$155.20M	$23.91M	$3.56B	$337.14M
7 Day Performance	-1.43%	3.05%	1.37%	-0.48%
1 Month Performance	16.46%	2.40%	0.81%	0.49%
1 Year Performance	459.64%	56.35%	30.53%	28.16%

Spyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYRE Spyre Therapeutics	1.6831 of 5 stars	$86.24 -11.1%	$95.83 +11.1%	+561.1%	$8.43B	$890K	N/A	73	Analyst Forecast Insider Trade Gap Down High Trading Volume
ONC BeOne Medicines	4.1189 of 5 stars	$276.13 +1.6%	$390.00 +41.2%	+7.2%	$30.30B	$5.34B	61.77	12,000
MRNA Moderna	1.2321 of 5 stars	$61.00 +2.8%	$36.60 -40.0%	+137.6%	$24.20B	$1.94B	N/A	4,700
ROIV Roivant Sciences	1.6094 of 5 stars	$32.21 +3.1%	$33.59 +4.3%	+180.1%	$23.17B	$8.26M	N/A	860	Positive News
BNTX BioNTech	4.5304 of 5 stars	$90.62 +0.5%	$129.56 +43.0%	-12.0%	$22.92B	$3.25B	N/A	7,807

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYRE) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyre Therapeutics (SYRE) Competitors

SYRE vs. ONC, MRNA, ROIV, BNTX, and INSM

How does Spyre Therapeutics compare to BeOne Medicines?

Summary

How does Spyre Therapeutics compare to Moderna?

Summary

How does Spyre Therapeutics compare to Roivant Sciences?

Summary

How does Spyre Therapeutics compare to BioNTech?

Summary

How does Spyre Therapeutics compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyre Therapeutics (SYRE) Competitors

SYRE vs. ONC, MRNA, ROIV, BNTX, and INSM

How does Spyre Therapeutics compare to BeOne Medicines?

Do analysts recommend ONC or SYRE?

Is ONC or SYRE more profitable?

Do institutionals and insiders have more ownership in ONC or SYRE?

Does the media prefer ONC or SYRE?

Which has preferable earnings and valuation, ONC or SYRE?

Which has more volatility & risk, ONC or SYRE?

Summary

How does Spyre Therapeutics compare to Moderna?

Do analysts rate MRNA or SYRE?

Which has more volatility & risk, MRNA or SYRE?

Does the media favor MRNA or SYRE?

Which has preferable valuation and earnings, MRNA or SYRE?

Do insiders & institutionals hold more shares of MRNA or SYRE?

Is MRNA or SYRE more profitable?

Summary

How does Spyre Therapeutics compare to Roivant Sciences?

Do insiders and institutionals believe in SYRE or ROIV?

Do analysts rate SYRE or ROIV?

Is SYRE or ROIV more profitable?

Which has more volatility and risk, SYRE or ROIV?

Does the media refer more to SYRE or ROIV?

Which has stronger valuation and earnings, SYRE or ROIV?

Summary

How does Spyre Therapeutics compare to BioNTech?

Do institutionals and insiders believe in SYRE or BNTX?

Which has higher valuation & earnings, SYRE or BNTX?

Do analysts rate SYRE or BNTX?

Is SYRE or BNTX more profitable?

Which has more risk and volatility, SYRE or BNTX?

Does the media refer more to SYRE or BNTX?

Summary

How does Spyre Therapeutics compare to Insmed?

Do institutionals and insiders believe in INSM or SYRE?

Is INSM or SYRE more profitable?

Which has more volatility & risk, INSM or SYRE?

Does the media favor INSM or SYRE?

Do analysts rate INSM or SYRE?

Which has preferable valuation and earnings, INSM or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools